Teva Pharmaceutical Industries (NYSE:TEVA) Insider Sells $1,928,780.00 in Stock

Posted by Francis Steltz on Nov 6th, 2026

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Get Free Report) insider Mark Sabag sold 46,000 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $41.93, for a total transaction of $1,928,780.00. Following the completion of the transaction, the insider directly owned 80,760 shares in the company, valued at approximately $3,386,266.80. This trade represents a 36.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Teva Pharmaceutical Industries Trading Up 1.8%

Shares of TEVA stock traded up $0.74 during trading hours on Friday, reaching $42.52. 6,131,455 shares of the stock traded hands, compared to its average volume of 6,848,926. The company has a quick ratio of 0.67, a current ratio of 0.95 and a debt-to-equity ratio of 1.59. The firm has a market capitalization of $49.55 billion, a PE ratio of 98.88, a PEG ratio of 3.92 and a beta of 0.97. Teva Pharmaceutical Industries Ltd. has a 1-year low of $23.61 and a 1-year high of $43.34. The business has a fifty day moving average price of $39.39 and a 200 day moving average price of $34.73.

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last posted its quarterly earnings data on Tuesday, November 3rd. The company reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.14. Teva Pharmaceutical Industries had a net margin of 2.94% and a return on equity of 33.20%. The firm had revenue of $4.39 billion during the quarter, compared to analyst estimates of $4.23 billion. During the same quarter last year, the business posted $0.78 EPS. The company’s revenue was down 1.9% on a year-over-year basis. On average, equities research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 1.98 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on TEVA shares. Oppenheimer lifted their price target on Teva Pharmaceutical Industries from $50.00 to $52.00 and gave the company an “outperform” rating in a report on Friday, October 9th. UBS Group raised their price objective on Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the stock a “buy” rating in a research report on Friday, September 4th. Zacks Research cut Teva Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 20th. Wall Street Zen downgraded Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Finally, Piper Sandler upped their target price on Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the company an “overweight” rating in a report on Tuesday, July 28th. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Teva Pharmaceutical Industries presently has an average rating of “Moderate Buy” and a consensus price target of $47.23.

Check Out Our Latest Report on TEVA

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Hedge funds have recently modified their holdings of the stock. Root Financial Partners LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the third quarter worth $33,000. Cornerstone Planning Group LLC grew its stake in Teva Pharmaceutical Industries by 547.1% in the first quarter. Cornerstone Planning Group LLC now owns 893 shares of the company’s stock valued at $27,000 after purchasing an additional 755 shares in the last quarter. Western Wealth Management LLC acquired a new position in Teva Pharmaceutical Industries in the 1st quarter worth about $43,000. Sunbelt Securities Inc. purchased a new stake in shares of Teva Pharmaceutical Industries during the 1st quarter worth about $45,000. Finally, CX Institutional bought a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at approximately $54,000. 54.05% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

Positive Sentiment: Teva said sales of its three key branded medicines grew 33% last quarter. The company also improved margins and reduced net debt, supporting its turnaround and financial position. Article: Teva’s 3 Key Branded Drugs Grew Sales 33% Last Quarter
Positive Sentiment: Teva’s third-quarter earnings beat estimates, and it raised its 2026 revenue and product-sales outlook, citing strength in branded drugs. The improved outlook may help offset the revenue decline. Article: Teva Q3 Earnings Beat Estimates, 2026 Revenue View Raised, Stock Up
Positive Sentiment: Analyst commentary is bullish: Leerink Partners raised its price target to $52 from $45 and maintained an outperform rating; HC Wainwright also reiterated a Buy rating and $52 target. TD Cowen was reported to see potential for further appreciation. Article: Leerink Partners Raises Teva Price Target Article: TD Cowen Forecasts Strong Price Appreciation
Negative Sentiment: Quarterly revenue slipped, a sign that growth remains uneven despite the stronger branded-drug performance and raised outlook. Article: Teva Stock: Q3 Revenue Slips as 2026 Outlook Rises

About Teva Pharmaceutical Industries

(Get Free Report)

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. Founded in 1901, the company is one of the world’s largest producers of generic medicines and develops, manufactures and distributes prescription products across a broad range of therapeutic areas.

Teva’s portfolio includes generic medicines, specialty pharmaceuticals, biosimilars, active pharmaceutical ingredients and over-the-counter products. Its specialty medicines include treatments for neurological and movement disorders, respiratory conditions, migraine and other chronic diseases.